与HPV表位体的TCR CDR3化学互补性与宫癌的更好的结果有关
Deo Rei L Agnila1, Rahul Jain1, Michael J Diaz1
1Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, 33612, USA.
概括
人类乳头瘤病毒 (HPV) T细胞受体对特定HPV表位体的互补性与宫癌患者的生存率改善有关. 这些发现表明HPV免疫治疗的潜在新点.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 病毒学 病毒学
背景情况:
- 尽管接种了HPV疫苗,但宫癌的发病率仍然存在,因此需要进一步研究治疗策略.
- 了解对人类乳头瘤病毒 (HPV) 的免疫反应对于开发新疗法至关重要.
- 适应性免疫受体分析为抗瘤免疫提供了洞察力.
研究的目的:
- 为了确定T细胞受体 (TCR) 互补性确定区域-3的 (CDR3s) 化学互补的人类乳头瘤病毒 (HPV) T细胞表位.
- 评估TCR CDR3与HPV表位体的互补性和宫癌患者的存活率之间的关联.
- 探索潜在的HPV表位作为未来癌症免疫治疗的目标.
主要方法:
- 利用来自TCGA和CGCI宫癌数据集的自适应性免疫受体序列.
- 分析了T细胞受体 (TCR) 互补性确定区域-3 (CDR3s) 对人类乳头瘤病毒 (HPV) T细胞表位的化学互补性.
- 相关的TCRCDR3互补性与多个数据集的整体生存概率.
主要成果:
- 在TCR CDR3与特定HPV表位体 (IEDB-1625373,IEDB-174148,IEDB-110943) 的化学互补性和总生存率的增加之间发现了一致的关联.
- 与HPV表位组的TCR互补性表明,在独立的宫癌队列中,存活率有好处.
- 确定了具有潜在治疗意义的特定HPV表位.
结论:
- 与某些HPV表位体的TCR-CDR3互补性是宫癌中改善生存率的重要预测因素.
- 这些发现突出了特定的HPV表位,作为开发新型免疫疗法的有希望的目标.
- 对针对HPV表观素的向疗法的进一步研究可能会降低宫癌死亡率.
更多相关视频
06:57Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
Published on: June 14, 2019
10.3K
09:53Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
Published on: February 6, 2017
11.4K
相关概念视频
Tumor Immunotherapy
406
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
406
Diversity of Antigen Receptors
387
Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
387
